These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 2325571)

  • 61. Bone responsiveness to parathyroid hormone in normal and osteoporotic postmenopausal women.
    Tsai KS; Ebeling PR; Riggs BL
    J Clin Endocrinol Metab; 1989 Nov; 69(5):1024-7. PubMed ID: 2793989
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The effect of calcitonin on biochemical markers and zinc excretion in postmenopausal osteoporosis.
    Colpan L; Gur A; Cevik R; Nas K; Sarac AJ
    Maturitas; 2005 Jul; 51(3):246-53. PubMed ID: 15978968
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Calcitriol in osteoporosis--is it used safely?
    Mathur G; Clifton-Bligh P; Fulcher G; Stiel J; McElduff A
    Aust N Z J Med; 1998 Jun; 28(3):348-9. PubMed ID: 9673752
    [No Abstract]   [Full Text] [Related]  

  • 64. The special role of "hormonal" forms of vitamin D in the treatment of osteoporosis.
    Nordin BE; Need AG; Morris HA; Horowitz M
    Calcif Tissue Int; 1999 Oct; 65(4):307-10. PubMed ID: 10485983
    [No Abstract]   [Full Text] [Related]  

  • 65. Treatment of postmenopausal osteoporosis with daily parathyroid hormone plus calcitriol.
    Neer M; Slovik DM; Daly M; Potts T; Nussbaum SR
    Osteoporos Int; 1993; 3 Suppl 1():204-5. PubMed ID: 8461561
    [No Abstract]   [Full Text] [Related]  

  • 66. Treatment of postmenopausal osteoporosis with 1,25-dihydroxyvitamin D3.
    Tilyard MW
    Osteoporos Int; 1993; 3 Suppl 1():194-5. PubMed ID: 8461557
    [No Abstract]   [Full Text] [Related]  

  • 67. Role of the active vitamin D metabolite and 1 alpha-hydroxylated analogs in the treatment of postmenopausal osteoporosis.
    Caniggia A; Loré F; Nuti R; Martini G; Frediani B; Di Cairano G
    J Nutr Sci Vitaminol (Tokyo); 1992; Spec No():232-5. PubMed ID: 1297745
    [No Abstract]   [Full Text] [Related]  

  • 68. Clinical update on calcitriol: introduction.
    Riggs BL
    Metabolism; 1990 Apr; 39(4 Suppl 1):1-2. PubMed ID: 2325563
    [No Abstract]   [Full Text] [Related]  

  • 69. The effect of calcitriol on patients with postmenopausal osteoporosis with special reference to fracture frequency.
    Gallagher JC; Riggs BL; Recker RR; Goldgar D
    Proc Soc Exp Biol Med; 1989 Jul; 191(3):287-92. PubMed ID: 2740360
    [No Abstract]   [Full Text] [Related]  

  • 70. Author response to: Comment on: Abdalbary et al. Impact of urinary calcium excretion on kidney, bone, and cardiovascular systems in patients with bone biopsy proven osteoporosis: a longitudinal long-term follow-up study.
    Abdalbary M; El-Husseini A
    Osteoporos Int; 2023 Oct; 34(10):1813. PubMed ID: 37578513
    [No Abstract]   [Full Text] [Related]  

  • 71. Retracted: Clinical Efficacy and Safety Evaluation of Calcitriol Combined with Bisphosphonates in the Therapy of Postmenopausal Osteoporosis: Based on a Retrospective Cohort Study.
    International BR
    Biomed Res Int; 2023; 2023():9781281. PubMed ID: 37475815
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Calcitriol. A review of its use in the treatment of postmenopausal osteoporosis and its potential in corticosteroid-induced osteoporosis.
    Dechant KL; Goa KL
    Drugs Aging; 1994 Oct; 5(4):300-17. PubMed ID: 7827399
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Calcitriol in the treatment of postmenopausal osteoporosis.
    Aloia JF; Vaswani A; Yeh JK; Ellis K; Yasumura S; Cohn SH
    Am J Med; 1988 Mar; 84(3 Pt 1):401-8. PubMed ID: 3279769
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The effects of high-dose calcitriol and individualized exercise on bone metabolism in breast cancer survivors on hormonal therapy: a phase II feasibility trial.
    Peppone LJ; Ling M; Huston AJ; Reid ME; Janelsins MC; Puzas JE; Kamen C; Del Giglio A; Asare M; Peoples AR; Mustian KM
    Support Care Cancer; 2018 Aug; 26(8):2675-2683. PubMed ID: 29470705
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The clinical use of vitamin D metabolites and their potential developments: a position statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF).
    Cianferotti L; Cricelli C; Kanis JA; Nuti R; Reginster JY; Ringe JD; Rizzoli R; Brandi ML
    Endocrine; 2015 Sep; 50(1):12-26. PubMed ID: 25931412
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The efficacy of calcitriol therapy in the management of bone loss and fractures: a qualitative review.
    Peppone LJ; Hebl S; Purnell JQ; Reid ME; Rosier RN; Mustian KM; Palesh OG; Huston AJ; Ling MN; Morrow GR
    Osteoporos Int; 2010 Jul; 21(7):1133-49. PubMed ID: 19960185
    [TBL] [Abstract][Full Text] [Related]  

  • 77. 2MD, a new anabolic agent for osteoporosis treatment.
    Plum LA; Fitzpatrick LA; Ma X; Binkley NC; Zella JB; Clagett-Dame M; DeLuca HF
    Osteoporos Int; 2006; 17(5):704-15. PubMed ID: 16491322
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Treatment of osteoporosis with vitamin D.
    Kanis JA; McCloskey EV; de Takats D; Bernard J; Zhang DM
    Osteoporos Int; 1997; 7 Suppl 3():S140-6. PubMed ID: 9536320
    [No Abstract]   [Full Text] [Related]  

  • 79. 1,25-Dihydroxyvitamin D3 in the pathogenesis and treatment of osteoporosis.
    DeLuca HF
    Osteoporos Int; 1997; 7 Suppl 3():S24-9. PubMed ID: 9536298
    [No Abstract]   [Full Text] [Related]  

  • 80. Prevention and management of osteoporosis. Current trends and future prospects.
    Compston JE
    Drugs; 1997 May; 53(5):727-35. PubMed ID: 9129862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.